Find drug development pipeline and deal Updates information

Lead Product(s): Temelimab

Therapeutic Area: Neurology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Bryan, Garnier & Co

Deal Size: $19.3 million Upfront Cash: Undisclosed

Deal Type: Investment January 31, 2020

Details:

Successfully completing this private placement provides GeNeuro the means to complete the planned study of temelimab in multiple sclerosis patients with disability progression without relapses.